Management of Community acquired pneumonia in the Emergency Room
Journal Title: Iberoamerican Journal of Medicine - Year 2019, Vol 1, Issue 1
Abstract
The incidence of community-acquired pneumonia (CAP) ranges from 2-15 cases/1,000 inhabitants/year, being higher in those over 65 or in patients with comorbidities. In Emergency Room (ER) it represents up to 1.35% of the care. Approximately 75% of all diagnosed CAPs are treated in ER. The CAP represents the origin of the majority of septic sepsis and shock diagnosed in ER, the leading cause of death and admission to the intensive care unit (ICU) for infectious disease. A global mortality of 10-14% is attributed according to age and associated risk factors. 40-60% of CAPs will require hospital admission, including observation areas (with very variable ranges of 22-65% according to centers, time of year and patient characteristics), and between them 2-10% will be in the ICU. From all that has been said, the importance of CAP in ER is translated, and also of the “impact of emergency care on patients with CAP”, as it is the device where initial, but fundamental, decisions are made for evolution of process. The great variability among clinicians in the management of diagnostic-therapeutic aspects in the CAP is known, which is one of the reasons that explain the large differences in admission rates, of achieving the microbiological diagnosis, request for complementary studies, the choice of antimicrobial regime or the diversity of care applied. In this sense, the implementation of clinical practice guidelines with the use of prognostic severity scales and the new tools available in HUSs such as biomarkers can improve the care of patients with CAP in ER. Therefore, based on a multidisciplinary group of emergency professionals and specialists participating in the CAP care process, this clinical guide has been designed with various recommendations for decisions and key moments in the process of patient care with NAC in the Emergency Room.
Authors and Affiliations
Eduardo Esteban-Zubero, Cristina García-Muro, Moisés A Alatorre-Jiménez, Alejandro Marín-Medina, Carlos Arturo López-García, Ahmed Youssef, Rocío Villeda-González
Keywords
Related Articles
- EP ID EP666516
- DOI 10.5281/zenodo.3402283
- Views 297
- Downloads 0
Medicinal plants: Prospective drug candidates against the dreaded Coronavirus
Introduction: Medicinal plants have been the most productive source of leads for the development of drugs from ancient times. Current research in drug discovery involves a multifaceted approach combining botanical, biolo...
The Novel Aspirin as Breakthrough Drug for COVID-19: A Narrative Review
Introduction: Aspirin has justifiably been called the first miracle drug. In this article, we highlight the history of Aspirin, a novel mechanism of action, and its use in cardiovascular and other diseases. Also included...
NMDA Receptors Subunits, Medical Conditions Involved in, and Their Roles as Drug Targets
In the 1960s, Jeff Watkins and colleagues discovered N-methyl-d-aspartate (NMDA) receptors, and since then, it has been a pharmacodynamic target for many neurological and psychiatric drugs. NMDA is a glutamate receptor a...
The dark side of Paediatric dentistry: Child abuse
Background: Children who have been abused could exhibit lesions and diseases in their oral cavity and develop psychological consequences towards the dentist-patient relationship. Objectives: Analyse the oral lesions and...
Application of diphenydramine ointment to the eyelids for allergic conjunctivitis
Introduction: Allergic conjunctivitis is treated with oral anti-allergy agents or topical eye drops, but the response is often incomplete, and symptoms persist. We considered that topical treatment with an antihistamine...